Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Sage Therapeutic Com (NQ: SAGE)
121.44 USD  -9.50 (-7.26%)
Official Closing Price  /  Updated: 6:52 PM EST, Nov 12, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 418,432
Open 130.39
Bid (Size) 116.01 (3)
Ask (Size) 117.99 (2)
Prev. Close 130.94
Today's Range 121.18 - 130.39
52wk Range 83.00 - 195.97
Shares Outstanding 46,515,858
Dividend Yield N/A
Performance
YTD
-27.13%
-27.13%
1 Month
-2.71%
-2.71%
3 Month
-18.90%
-18.90%
6 Month
-29.75%
-29.75%
1 Year
+28.30%
+28.30%
Top News
More News
Sage Therapeutics to Present at Stifel 2018 Healthcare Conference
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company... Read More
from Business Wire News Releases
Sage Therapeutics Announces Third Quarter 2018 Financial Results and Highlights Pipeline and Business Progress
Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business... Read More
from Business Wire News Releases
More News
Read More
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
from Business Wire News Releases
Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 in Support of Benefit-Risk Profile of ZULRESSO™ (brexanolone) Injection for Treatment of Postpartum Depression
from Business Wire News Releases
Stocks making the biggest moves after hours: PG&E, Eventbrite and more
category Business/Earnings , Symantec Corp , Eventbrite Inc , and 10 more.
from CNBC.com News
Sage Therapeutics Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss ZULRESSO™ (brexanolone) Injection for the Treatment of Postpartum Depression
from Business Wire News Releases
UPDATE 2-FDA panel recommends Sage's postpartum depression treatment
category companyNews
from Reuters: Company News
Morning Call For Monday, Nov. 5
category Bonds , Stocks / Equities , Commodities , and 1 more.
from Blogs - TalkMarkets
UPDATE 1-Sage's postpartum depression treatment benefits outweigh risk: FDA panel
category companyNews
from Reuters: Company News
Sage's postpartum depression treatment benefits outweigh risk: FDA panel
category companyNews
from Reuters: Company News
Noteworthy Thursday Option Activity: PII, SAGE, INFN
category Stocks
from Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.